Showing results (231-240 of 249) with videos related to
Sort By:
Pageof 25
Circulation. Genomic and Precision Medicine|January 24, 2025
Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic CardiomyopathyAlexandra Butters, Clare Arnott, Joanna Sweeting, et al.JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|October 6, 2025
Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concernsDennis J Keselman, Juliana C Small, Tiffany Seneviratne, et al.American Journal of Human Genetics|January 13, 2022
The genetic architecture of pediatric cardiomyopathyStephanie M Ware, Surbhi Bhatnagar, Phillip J Dexheimer, et al.American Heart Journal|June 14, 2023
Cardiac imaging and biomarkers for assessing myocardial fibrosis in children with hypertrophic cardiomyopathySonya Kirmani, Pamela K Woodard, Ling Shi, et al.Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|May 7, 2025
Current clinical applications of AAV-mediated gene therapyBarry J Byrne, Kevin M Flanigan, Susan E Matesanz, et al.Journal of the American Heart Association|April 28, 2021
Genetic Causes of Cardiomyopathy in Children: First Results From the Pediatric Cardiomyopathy Genes StudyStephanie M Ware, James D Wilkinson, Muhammad Tariq, et al.JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.Pageof 25